Dr Mark Greene has contributed extensively to our understanding of the role of erbB gene family in mammalian cell growth and neoplasia. His contributions include the delineation of mechanisms associated with oligomerization and diversi®cation processes of the erbB family of proteins and signal transduction pathways mediated by this family of receptors. His other contributions include the development of monoclonal antibodies speci®c for the ectodomain of p185 and demonstration of their utility in cancer therapy. His laboratory was the ®rst to develop organic synthetic antibody like forms that are eective in models of human breast cancer and may be amenable to oral delivery. Recent eorts from Greene's laboratory have been to link the pathways relevant to heritable breast cancer formation with those that are active in the genesis of sporadic breast tumors. His group and Richard Fishel's laboratory have linked MSH2 dependent repair of damaged DNA with BRCA1 activities. This set of studies and his eorts in elucidating erbB determined processes have supported the principle of biochemical linkage of certain shared heritable and sporadic processes involved in breast cancer development.
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